Newsroom

NIH Awards $1.7 Million Grant for Celdara Medical and Pulmatrix to Develop an Inhaled Biologic Treatment for Idiopathic Pulmonary Fibrosis

Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million Fast Track Small Business Innovation Research grant to fund the companies’ development of an inhaled biologic to treat idiopathic pulmonary […]

Continue Reading

Celdara Medical Wins 2015 Tibbetts Award

Celdara Medical, LLC announced today that it has received national recognition from the Small Business Administration (SBA) in the form of a Tibbetts Award. The award recognizes unique contributions to the Small Business Innovation Research (SBIR) Program.  John Williams, the Director of Innovation and Technology in the Office of Investment […]

Continue Reading

Celdara Medical, LLC’s CM-CLS IND is Active

Celdara Medical, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of CM-CS1 in patients with Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM). Celdara Medical plans to initiate a […]

Continue Reading

Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas. Virtici and Celdara Medical are affiliated, independent companies that build and develop […]

Continue Reading

Enquire now

Give us a call or fill in the form below and we'll contact you. We endeavor to answer all inquiries within 24 hours on business days.